Emerging MEK inhibitors-Reference-Cited by-同舟云学术

Emerging MEK inhibitors

Published:2010-02-13 Issue:2 Volume:15 Page:203-223
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

McCubrey James A,Steelman Linda S,Abrams Steven L,Chappell William H,Russo Suzanne,Ove Roger,Milella Michele,Tafuri Agostino,Lunghi Paolo,Bonati Antonio,Stivala Franca,Nicoletti Ferdinando,Libra Massimo,Martelli Alberto M,Montalto Giuseppe,Cervello Melchiorre

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1517/14728210903282760

Reference109 articles.

1. Emerging Raf inhibitors

2. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

3. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KRAS is a molecular determinant of platinum responsiveness in glioblastoma;BMC Cancer;2024-01-15

2. Paradoxical effects of statins on endothelial and cancer cells: the impact of concentrations;Cancer Cell International;2023-03-10

3. The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer;Frontiers in Oncology;2021-10-04

4. Extracellular Signal-Regulated Kinase: A Regulator of Cell Growth, Inflammation, Chondrocyte and Bone Cell Receptor-Mediated Gene Expression;International Journal of Molecular Sciences;2019-08-03

5. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway;International Journal of Molecular Sciences;2019-03-07